Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,522 INR | +0.47% |
|
+3.82% | +20.83% |
06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
06-25 | Sun Pharma Completes Taro Pharmaceutical Industries Merger | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.91 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.83% | 43.77B | - | ||
+28.00% | 22.83B | B+ | ||
+20.25% | 15.56B | - | ||
+18.82% | 14.34B | B+ | ||
+55.83% | 12.96B | B | ||
-0.05% | 6.79B | - | - | |
-12.70% | 6.41B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.65% | 5.69B | B+ | ||
+9.49% | 4.75B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SUNPHARMA Stock
- SUNPHARMA Stock
- Ratings Sun Pharmaceutical Industries Ltd.